Clinical characteristics and antimicrobial susceptibilities of anaerobic bacteremia in an acute care hospital

Anaerobe

Volumn 43, Issue , 2017, Pages 69-74

  Tan, Thean Yen ^a   Ng, Lily Siew Yong ^a   Kwang, Lee Ling ^a   Rao, Suma ^a   Eng, Li Ching ^a  

^a CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

Anaerobes; Antibiotic resistance; Bacteremia; Bacteroides

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE INHIBITOR; CLINDAMYCIN; IMIPENEM; METRONIDAZOLE; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ABDOMINAL INFECTION; ADULT; AGED; ANAEROBIC BACTERIUM; ANAEROBIC INFECTION; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL GENE; BACTEROIDES FRAGILIS; BLOOD CULTURE; CFIA GENE; CLINICAL STUDY; CLOSTRIDIUM; COMMUNITY ACQUIRED INFECTION; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD SYSTEM; EMERGENCY CARE; EPSILOMETER TEST; FUSOBACTERIUM; HOSPITAL; HOSPITAL ADMISSION; HUMAN; LEMIERRE SYNDROME; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MORTALITY; NIM GENE; NONHUMAN; PRIORITY JOURNAL; PROPIONIBACTERIUM; RESIDENTIAL CARE; RETROSPECTIVE STUDY; SOFT TISSUE INFECTION; SURVIVAL; ANAEROBIC GROWTH; ANALOGS AND DERIVATIVES; ANTIBIOTIC RESISTANCE; BACTEROIDES; DRUG EFFECTS; GRAM POSITIVE BACTERIUM; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANAEROBIOSIS; ANTI-INFECTIVE AGENTS; BACTEREMIA; BACTERIA, ANAEROBIC; BACTEROIDES; CARBAPENEMS; CLINDAMYCIN; CLOSTRIDIUM; DRUG RESISTANCE, MICROBIAL; FUSOBACTERIUM; GRAM-POSITIVE BACTERIA; HUMANS; INTRAABDOMINAL INFECTIONS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN; PROPIONIBACTERIUM; RETROSPECTIVE STUDIES;

EID: 85006778810     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2016.11.009     Document Type: Article

References (20)

1. [1] Fenner, L., Widmer, A.F., Straub, C., Frei, R., Is the incidence of anaerobic bacteremia decreasing? Analysis of 114,000 blood cultures over a ten-year period. J. Clin. Microbiol. 46 (2008), 2432–2434.
2. [2] Lassmann, B., Gustafson, D.R., Wood, C.M., Rosenblatt, J.E., Reemergence of anaerobic bacteremia. Clin. Infect. Dis. 44 (2007), 895–900.
3. [3] Salonen, J.H., Eerola, E., Meurman, O., Clinical significance and outcome of anaerobic bacteremia. Clin. Infect. Dis. 26 (1998), 1413–1417.
4. [4] Blairon, L., De Gheldre, Y., Delaere, B., Sonet, A., Bosly, A., Glupczynski, Y.A., 62-month retrospective epidemiological survey of anaerobic bacteraemia in a university hospital. Clin. Microbiol. Infect. 12 (2006), 527–532.
5. [5] Goldstein, E.J.C., Citron, D.M., Resistance trends in antimicrobial susceptibility of anaerobic bacteria. Part i. Clin. Microbiol. Newsl. 33 (2011), 1–8.
6. [6] Liu, C.Y., Huang, Y.T., Liao, C.H., Yen, L.C., Lin, H.Y., Hsueh, P.R., Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob. Agents Chemother. 52 (2008), 3161–3168.
7. [7] Nguyen, M.H., Yu, V.L., Morris, A.J., McDermott, L., Wagener, M.W., Harrell, L., et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin. Infect. Dis. 30 (2000), 870–876.
8. [8] Brook, I., Frazier, E.H., Significant recovery of nonsporulating anaerobic rods from clinical specimens. Clin. Infect. Dis. official Publ. Infect. Dis. Soc. Am. 16 (1993), 476–480.
9. [9] Park, H.J., Na, S., Park, S.Y., Moon, S.M., Cho, O.H., Park, K.H., et al. Clinical significance of Propionibacterium acnes recovered from blood cultures: analysis of 524 episodes. J. Clin. Microbiol. 49 (2011), 1598–1601.
10. [10] CLSI, Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria. 2012, Clinical and Laboratory Standards Institute, Wayne, PA Approved Standard - Eighth Edition. CLSI document M11–A8.
11. [11] Trinh, S., Reysset, G., Detection by PCR of the nim genes encoding 5-nitroimidazole resistance in Bacteroides spp. J. Clin. Microbiol. 34 (1996), 2078–2084.
12. [12] Thompson, J.S., Malamy, M.H., Sequencing the gene for an imipenem-cefoxitin-hydrolyzing enzyme (CfiA) from Bacteroides fragilis TAL2480 reveals strong similarity between CfiA and Bacillus cereus beta-lactamase II. J. Bacteriol. 172 (1990), 2584–2593.
13. [13] Hall, W.H., Ramachandran, R., Narayan, S., Jani, A.B., Vijayakumar, S., An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer, 4, 2004, 94.
14. [14] Dean, A.G.S.K., Soe, M.M., OpenEpi: Open Source Epidemiologic Statistics for Public Health. Version 3.01, 2013.
15. [15] Muttaiyah, S., Paviour, S., Buckwell, L., Roberts, S.A., Anaerobic bacteraemia in patients admitted to Auckland City Hospital: its clinical significance. N. Z. Med. J., 120, 2007, U2809.
16. [16] Brook, I., The role of anaerobic bacteria in bacteremia. Anaerobe 16 (2010), 183–189.
17. [17] Snydman, D.R., Jacobus, N.V., McDermott, L.A., Golan, Y., Hecht, D.W., Goldstein, E.J., et al. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). Clin. Infect. Dis. 50:Suppl 1 (2010), S26–S33.
18. [18] Ang, L., Brenwald, N.P., Walker, R.M., Andrews, J., Fraise, A., Carbapenem resistance in Bacteroides fragilis. J. Antimicrob. Chemother. 59 (2007), 1042–1044.
19. [19] Lofmark, S., Edlund, C., Nord, C.E., Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin. Infect. Dis. official Publ. Infect. Dis. Soc. Am. 50:Suppl 1 (2010), S16–S23.
20. [20] Boyanova, L., Kolarov, R., Mitov, I., Recent evolution of antibiotic resistance in the anaerobes as compared to previous decades. Anaerobe 31 (2015), 4–10.